Literature DB >> 7834636

Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.

H Oda1, Y Nakatsuru, T Ishikawa.   

Abstract

Renal cell carcinomas sometimes show sarcomatoid transformation, thus comprising both sarcomatous and carcinomatous components. Such sarcomatoid renal cell carcinomas are highly malignant with pronounced proliferative activity. The present investigation was conducted to assess the mutational status of the p53 and H-ras genes independently in carcinomatous and sarcomatous portions of individual tumors, applying PCR, subcloning, and sequencing to 14 cases. Sarcomatoid portions showed an extremely high mutation rate for the 53 gene (11 of 14, 78.6%) with two mutational hot spots at codons 278 (8 of 14, 57.1%) and 244 (6 of 14, 42.9%). Five cases showed double mutations, four cases had mutations at codons 278 and 244, and one case had mutations at codons 278 and 248. In contrast, the carcinomatous portions demonstrated a low mutation rate for the p53 gene (2 of 14, 14.3%) and no double mutations were detected. Ten cases showed genetic heterogeneity in the p53 gene between the two tumor components. Furthermore, p53 overexpression was immunohistochemically observed only in those components with p53 mutations, mainly in the sarcomatoid portions. No H-ras mutations were observed. The findings strongly suggest that p53 mutations leading to overexpression of p53 protein are closely associated with sarcomatoid transformation in renal cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834636

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Authors:  Youfeng Yang; Cathy D Vocke; Christopher J Ricketts; Darmood Wei; Hesed M Padilla-Nash; Martin Lang; Carole Sourbier; J Keith Killian; Shawna L Boyle; Robert Worrell; Paul S Meltzer; Thomas Ried; Maria J Merino; Adam R Metwalli; W Marston Linehan
Journal:  Genes Chromosomes Cancer       Date:  2017-07-24       Impact factor: 5.006

2.  Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components.

Authors:  Brandon J Manley; James J Hsieh
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

3.  Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Authors:  Abhishek Maiti; Maryam Nemati-Shafaee; Pavlos Msaouel; Lance C Pagliaro; Eric Jonasch; Nizar M Tannir; Amishi Y Shah
Journal:  Clin Genitourin Cancer       Date:  2017-08-10       Impact factor: 2.872

4.  Immune and genetic therapies for advanced renal cell carcinoma.

Authors:  A Zisman; A J Pantuck; A Belldegrun
Journal:  Rev Urol       Date:  2000

5.  Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Authors:  Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-10       Impact factor: 11.205

Review 6.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.

Authors:  Brian Shuch; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Oncologist       Date:  2012-01-10

Review 7.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 8.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

Review 9.  Molecular-based therapies for renal cell carcinoma.

Authors:  A Zisman; A J Pantuck; A S Belldegrun
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 3.092

10.  Proliferative heterogeneity of human renal cell carcinomas and prevalence of ras gene point mutations.

Authors:  V Waldmann; H M Rabes
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.